Cargando…
Challenges of CAR- and TCR-T cell–based therapy for chronic infections
While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201928/ https://www.ncbi.nlm.nih.gov/pubmed/32163104 http://dx.doi.org/10.1084/jem.20191663 |